Two High to Start? Targeting a New Starting Dose for Argatroban Infusions

Abstract

Get full access to this article

View all access options for this article.

References

Smythe

Koerber

Forsyth

Priziola

Balasubramaniam

Mattson

JC.

Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy. 2009;29:1073-1081. doi:10.1592/phco.29.9.1073

Gilmore

Adams

Blum

Fanikos

Anne Hirning

Matta

Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia. Am J Hematol. 2015;90:E143-E145. doi:10.1002/ajh.24042

Aljabri

Huckleberry

Karnes

, et al. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood. 2016;128:3043-3051. doi:10.1182/blood-2016-07-728030

Doepker

Mount

Ryder

Gerlach

Murphy

Philips

GS.

Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis. 2012;34:491-498. doi:10.1007/s11239-012-0758-y